Clinical-stage biopharmaceutical company Zosano Pharma Corporation announced a partnership with EVERSANA, a leading provider of commercial services to the life science industry, to commercialize and distribute Qtrypta in the United States.
The U.S. Food and Drug Administration issued a Complete Response Letter regarding DBV Technologies’ Biologics License Application (BLA) for investigational Viaskin Peanut (DBV712), a non-invasive, once-daily epicutaneous patch to treat peanut allergies in children ages 4 to 11 years.
A group of tech companies is working on a patch about the size of a small bandage that could be worn to monitor for the elevated body temperatures that can sometimes signal the onset of COVID-19.
A smart insulin device under development could revolutionize how glucose levels are monitored in diabetes patients and deliver insulin doses when necessary.
Noven Pharmaceuticals won approval from the U.S. Food and Drug Administration for the company’s transdermal schizophrenia patch.
After an eight month delay, France-based DBV Technologies announced the resubmission of a Biologics License Application to the U.S. FDA for the non-invasive allergy patch Viaskin Peanut.
The U.S. FDA approved Amneal Pharmaceuticals’ generic version of Novartis’ Exelon Patch (Rivastigmine Transdermal System) for dementia related to Alzheimer’s and Parkinson’s diseases.
Aequus Pharmaceuticals Inc. announced an expansion of its relationship with Corium International Inc. to include the company’s long-acting transdermal patch AQS1303 for the treatment of nausea and vomiting in pregnancy.
France’s competition authority fined U.S. healthcare group Johnson & Johnson 25 million euros ($29.6 million) after it ruled the company had deliberately slowed market access to generic copies of its painkiller Durogesic.
The biopharma industry and the U.S. Food and Drug Administration face a busy December with nine companies awaiting approval decisions.